A phase 2 study of Pelareorep in combination with pembrolizumab (KEYTRUDA®) in patients with relapsed metastatic adenocarcinoma of the pancreas.
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2018
At a glance
- Drugs Pelareorep (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Merck & Co
- 14 Mar 2018 New trial record
- 09 Mar 2018 According to an Oncolytics Biotech media release, this study is expected to start in 2Q 2018.